Literature DB >> 29913471

Andexxa--an antidote for apixaban and rivaroxaban.

.   

Abstract

Entities:  

Keywords:  Andexxa; Arixtra; Bevyxxa; DOAC; Eliquis; NOAC; Pradaxa; Praxbind; Savaysa; Xarelto; adverse effects; andexanet; apixaban; betrixaban; dabigatran; dosage; edoxaban; efficacy; enoxaparin; fondaparinux; idarucizumab; rivaroxaban; safety

Mesh：

Substances：

Year:  2018        PMID： 29913471

Source DB:  PubMed          Journal:  Med Lett Drugs Ther        ISSN： 0025-732X            Impact factor:   1.909


× No keyword cloud information.
  3 in total

Review 1.  Biological Products: Cellular Therapy and FDA Approved Products.

Authors:  Ali Golchin; Tahereh Zarnoosheh Farahany
Journal:  Stem Cell Rev Rep       Date:  2019-04       Impact factor: 5.739

2.  Combining Heparin and a FX/Xa Aptamer to Reduce Thrombin Generation in Cardiopulmonary Bypass and COVID-19.

Authors:  Charlene V Chabata; James W Frederiksen; Lyra B Olson; Ibtehaj A Naqvi; Sharon E Hall; Ruwan Gunaratne; Bryan D Kraft; Loretta G Que; Lingye Chen; Bruce A Sullenger
Journal:  Nucleic Acid Ther       Date:  2022-01-12       Impact factor: 4.244

3.  Costs and Healthcare Resource Utilization Associated with Idarucizumab or Andexanet Alfa Oral Anticoagulant Reversal in Patients Hospitalized with Life-Threatening Bleeds.

Authors:  Alex C Spyropoulos; Bríain Ó Hartaigh; Zhun Cao; Harjeet Caberwal; Craig Lipkin; Michaela Petrini; Cheng Wang
Journal:  Clin Appl Thromb Hemost       Date:  2022 Jan-Dec       Impact factor: 3.512
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.